Vir Biotechnology
Focus: Vir Biotechnology is a San Francisco-based biotech focused on infectious disease therapies with a diversified pipeline spanning COVID-19, influenza, hepatitis B/D, and emerging oncology programs. The company is positioned as a clinical-stage to early-commercial biotech with multiple assets advancing through Phase 2–3 development.
Profile data last refreshed 13h ago · AI intelligence enriched 2mo ago
Open Jobs
19
Should You Work at Vir Biotechnology?
AI assessmentBest fit for career-builders seeking high-impact infectious disease exposure in a growth-stage biotech; not ideal for those prioritizing near-term revenue stability or commercial-launch experience.
Why Work Here
- Deep infectious disease expertise with 30 pipeline programs across COVID-19, influenza, hepatitis, and HIV, offering exposure to high-impact therapeutic areas.
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Late-stage
5 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Sotrovimab
Covid19Clinical Trials (1)
NCT05235347Sotrovimab Expanded Access Treatment Protocol (COVID-19)
N/AHelp build intelligence for Vir Biotechnology
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.